Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage

David L. Brody, Venkatesh Aiyagari, Angela M. Shackleford, Michael N. Diringer

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Introduction: Warfarin-associated intracranial hemorrhage (ICH) requires rapid normalization of clotting function. Current therapies are associated with significant complications and/or prolonged time to correction of coagulopathy. Recombinant factor VIIa (FVIIa) might allow faster and safer correction of coagulopathy. Methods: This article presents a retrospective chart review of all patients with warfarin-associated ICH treated in a neurology/neurosurgery intensive care unit over an 11-month period. Results: All patients were treated to rapidly reverse the warfarin effect. Fifteen patients received vitamin K and fresh frozen plasma (FFP) alone (FFP group). Twelve patients also received FVIIa (FVIIa group). The median times from presentation to an international normalization ratio (INR) of less than 1.3 were 32.2 and 8.8 hours in the FFP the FVIIa groups, respectively (p = 0.016). INR normalized slowly (at 110 and 130 hours, respectively) in two patients with end-stage renal failure who were given FVIIa, one of whom developed disseminated intravascular coagulation after three doses of FVIIa. No other complications occurred from FVIIa administration. One patient in the FFP group developed severe pulmonary edema. Conclusion: FVIIa may be an effective adjunct to FFP in warfarin-related ICH, facilitating faster correction of INR and decreasing FFP requirements. A prospective, randomized trial is needed to confirm these preliminary findings and to determine whether there is a clinical benefit.

Original languageEnglish (US)
Pages (from-to)263-267
Number of pages5
JournalNeurocritical Care
Volume2
Issue number3
DOIs
StatePublished - Jun 2005

Fingerprint

Factor VIIa
Intracranial Hemorrhages
Warfarin
International Normalized Ratio
Vitamin K
Disseminated Intravascular Coagulation
Neurosurgery
Pulmonary Edema
Neurology
recombinant FVIIa
Chronic Kidney Failure
Intensive Care Units

Keywords

  • Coagulopathy
  • Factor VIIa
  • Fresh frozen plasma
  • Intracranial hemorrhage
  • Warfarin

ASJC Scopus subject areas

  • Clinical Neurology
  • Critical Care and Intensive Care Medicine

Cite this

Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. / Brody, David L.; Aiyagari, Venkatesh; Shackleford, Angela M.; Diringer, Michael N.

In: Neurocritical Care, Vol. 2, No. 3, 06.2005, p. 263-267.

Research output: Contribution to journalArticle

Brody, David L. ; Aiyagari, Venkatesh ; Shackleford, Angela M. ; Diringer, Michael N. / Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. In: Neurocritical Care. 2005 ; Vol. 2, No. 3. pp. 263-267.
@article{5968c1f7153b4b879b3b02a9aa3d1eec,
title = "Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage",
abstract = "Introduction: Warfarin-associated intracranial hemorrhage (ICH) requires rapid normalization of clotting function. Current therapies are associated with significant complications and/or prolonged time to correction of coagulopathy. Recombinant factor VIIa (FVIIa) might allow faster and safer correction of coagulopathy. Methods: This article presents a retrospective chart review of all patients with warfarin-associated ICH treated in a neurology/neurosurgery intensive care unit over an 11-month period. Results: All patients were treated to rapidly reverse the warfarin effect. Fifteen patients received vitamin K and fresh frozen plasma (FFP) alone (FFP group). Twelve patients also received FVIIa (FVIIa group). The median times from presentation to an international normalization ratio (INR) of less than 1.3 were 32.2 and 8.8 hours in the FFP the FVIIa groups, respectively (p = 0.016). INR normalized slowly (at 110 and 130 hours, respectively) in two patients with end-stage renal failure who were given FVIIa, one of whom developed disseminated intravascular coagulation after three doses of FVIIa. No other complications occurred from FVIIa administration. One patient in the FFP group developed severe pulmonary edema. Conclusion: FVIIa may be an effective adjunct to FFP in warfarin-related ICH, facilitating faster correction of INR and decreasing FFP requirements. A prospective, randomized trial is needed to confirm these preliminary findings and to determine whether there is a clinical benefit.",
keywords = "Coagulopathy, Factor VIIa, Fresh frozen plasma, Intracranial hemorrhage, Warfarin",
author = "Brody, {David L.} and Venkatesh Aiyagari and Shackleford, {Angela M.} and Diringer, {Michael N.}",
year = "2005",
month = "6",
doi = "10.1385/NCC:2:3:263",
language = "English (US)",
volume = "2",
pages = "263--267",
journal = "Neurocritical Care",
issn = "1541-6933",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage

AU - Brody, David L.

AU - Aiyagari, Venkatesh

AU - Shackleford, Angela M.

AU - Diringer, Michael N.

PY - 2005/6

Y1 - 2005/6

N2 - Introduction: Warfarin-associated intracranial hemorrhage (ICH) requires rapid normalization of clotting function. Current therapies are associated with significant complications and/or prolonged time to correction of coagulopathy. Recombinant factor VIIa (FVIIa) might allow faster and safer correction of coagulopathy. Methods: This article presents a retrospective chart review of all patients with warfarin-associated ICH treated in a neurology/neurosurgery intensive care unit over an 11-month period. Results: All patients were treated to rapidly reverse the warfarin effect. Fifteen patients received vitamin K and fresh frozen plasma (FFP) alone (FFP group). Twelve patients also received FVIIa (FVIIa group). The median times from presentation to an international normalization ratio (INR) of less than 1.3 were 32.2 and 8.8 hours in the FFP the FVIIa groups, respectively (p = 0.016). INR normalized slowly (at 110 and 130 hours, respectively) in two patients with end-stage renal failure who were given FVIIa, one of whom developed disseminated intravascular coagulation after three doses of FVIIa. No other complications occurred from FVIIa administration. One patient in the FFP group developed severe pulmonary edema. Conclusion: FVIIa may be an effective adjunct to FFP in warfarin-related ICH, facilitating faster correction of INR and decreasing FFP requirements. A prospective, randomized trial is needed to confirm these preliminary findings and to determine whether there is a clinical benefit.

AB - Introduction: Warfarin-associated intracranial hemorrhage (ICH) requires rapid normalization of clotting function. Current therapies are associated with significant complications and/or prolonged time to correction of coagulopathy. Recombinant factor VIIa (FVIIa) might allow faster and safer correction of coagulopathy. Methods: This article presents a retrospective chart review of all patients with warfarin-associated ICH treated in a neurology/neurosurgery intensive care unit over an 11-month period. Results: All patients were treated to rapidly reverse the warfarin effect. Fifteen patients received vitamin K and fresh frozen plasma (FFP) alone (FFP group). Twelve patients also received FVIIa (FVIIa group). The median times from presentation to an international normalization ratio (INR) of less than 1.3 were 32.2 and 8.8 hours in the FFP the FVIIa groups, respectively (p = 0.016). INR normalized slowly (at 110 and 130 hours, respectively) in two patients with end-stage renal failure who were given FVIIa, one of whom developed disseminated intravascular coagulation after three doses of FVIIa. No other complications occurred from FVIIa administration. One patient in the FFP group developed severe pulmonary edema. Conclusion: FVIIa may be an effective adjunct to FFP in warfarin-related ICH, facilitating faster correction of INR and decreasing FFP requirements. A prospective, randomized trial is needed to confirm these preliminary findings and to determine whether there is a clinical benefit.

KW - Coagulopathy

KW - Factor VIIa

KW - Fresh frozen plasma

KW - Intracranial hemorrhage

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=23444448265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23444448265&partnerID=8YFLogxK

U2 - 10.1385/NCC:2:3:263

DO - 10.1385/NCC:2:3:263

M3 - Article

VL - 2

SP - 263

EP - 267

JO - Neurocritical Care

JF - Neurocritical Care

SN - 1541-6933

IS - 3

ER -